Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00012337 · ClinicalTrials.gov registry record · Phase 2
ZD 1839 in Treating Patients With Metastatic Kidney Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00012337: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00012337 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00012337, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have metastatic kidney cancer.
Interventions
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-01 |
| Est. Completion | 2004-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00012337
The ClinicalTrials.gov registry entry for NCT00012337 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gefitinib is the first listed.
NCT00012337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00012337 about?
NCT00012337 is a clinical study titled "ZD 1839 in Treating Patients With Metastatic Kidney Cancer". RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have metastatic kidne...
What is the current status of trial NCT00012337?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-01. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00012337?
The interventions under investigation include: gefitinib (DRUG).
Who is sponsoring clinical trial NCT00012337?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.